Document:

Exhibit 4.1

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

	No.
    [___]	[DATE]

 

NeuroOne
Medical Technologies Corporation

 

[Form
of] Common Stock Purchase Warrant

_________________

 

This
Certifies That, for value received, [NAME],
or his/her/our registered assigns (the “Purchaser”), is entitled to subscribe for and purchase from
NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”),
at any time commencing on [DATE] and expiring on [five year anniversary date] (such period, the “Warrant Exercise
Term”), the Shares at the Exercise Price (each as defined in Section 1 below).

 

This
Warrant is issued in connection with the Company’s private placement solely to accredited investors of units, each consisting
of 1 share of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and
a warrant to purchase 1 share of Common Stock, (the “Private Placement”), which may be issued in one
or more closings, in accordance with, and subject to, the terms and conditions described in the Subscription Agreement, dated
as of even date herewith (the “Subscription Agreement”). Capitalized terms used and not otherwise defined
herein shall have the respective meanings assigned to such terms in the Subscription Agreement. 

 

This
Warrant is subject to the following terms and conditions:

 

1. Shares.
The Purchaser has, subject to the terms set forth herein, the right to purchase, at any time during the Warrant Exercise Term,
up to [NUMBER OF SHARES] shares of Common Stock, at a per share exercise price of $3.00 (as the same may be adjusted as provided
in Section 3 hereof, the “Exercise Price”). The shares of Common Stock received upon any exercise
of this Warrant are referred to herein as the “Shares”.

 

    

    

    

 

2. Exercise
of Warrant. 

 

(a) Exercise.
This Warrant may be exercised by the Purchaser at any time during the Warrant Exercise Term, in whole or in part, by delivering
to the Company at its principal office, or at such other office as the Company may designate (i) the notice of exercise attached
as Exhibit A hereto (the “Notice of Exercise”),
duly executed by the Purchaser and (ii) this Warrant certificate, accompanied by (iii) payment, in cash or by wire transfer of
immediately available funds or by check payable to the order of the Company of the amount obtained by multiplying the number of
Shares designated in the Notice of Exercise by the Exercise Price (the “Purchase Price”). For purposes
hereof, “Exercise Date” shall mean the date on which all deliveries required to be made to the Company
upon exercise of this Warrant pursuant to this Section 2(a) shall have been made. In no event shall the Company be required
to net cash settle any Warrant exercise.

 

(b) Redemption.

 

(i)All
of the outstanding Warrants (but not less than all) may be redeemed, at the option of the Company, at any time beginning after
the one-year anniversary of the date hereof and during the Warrant Exercise Term upon notice to the Purchaser at the price of
$3.00 per Warrant (the “Redemption Price”), provided that the VWAP (as defined below) of the Common
Stock is at least 200% of the Exercise Price for 20 consecutive Trading Days prior to the date on which notice of the redemption
is given. “VWAP” means, for any date, the price determined by the first of the following clauses that
applies: (A) if the Common Stock is then listed or quoted on a Trading Market (other than the OTC Bulletin Board or OTC Markets,
Inc.), the daily volume weighted average price of the Common Stock for such date (or the nearest preceding Trading Day) on the
Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (B) if the Common Stock is then quoted on the OTC Bulletin Board,
the volume weighted average price of the Common Stock for such date (or the nearest preceding Trading Day) on the OTC Bulletin
Board, (C) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common
Stock are then reported on OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per share of the Common Stock so reported, or (D) in all other cases, the fair market value of
a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest
of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the
Company. “Trading Day” means a day on which the principal Trading Market is open for trading. “Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading
on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
New York Stock Exchange (or any successors to any of the foregoing), the OTC Bulletin Board or OTC Markets, Inc.

 

(ii)The
Company shall fix a date for the redemption (the “Redemption Date”). Notice of redemption shall be mailed
by first class mail, postage prepaid, by the Company not less than 30 days prior to the Redemption Date to the Purchasers
to be redeemed at their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein
provided shall be conclusively presumed to have been duly given whether or not the Purchaser received such notice.

 

    2

    

    

 

(iii)The
notice of redemption shall contain the information necessary to calculate the number of Shares to be received upon exercise of
the Warrants, including the VWAP calculations. On and after the Redemption Date, the record holder of the Warrants shall have
no further rights except to receive, upon surrender of the Warrants, the Redemption Price.

 

(c) Issuance
of Certificates. As soon as practicable after the exercise of this Warrant, in whole or in part, in accordance with Section
2(a) hereof, the Company, at its expense, shall cause to be issued in the name of and delivered to the Purchaser (i) a certificate
or certificates for the number of validly issued, fully paid and non-assessable Shares to which the Purchaser shall be entitled
upon such exercise and, if applicable and (ii) a new warrant of like tenor to purchase all of the Shares that may be purchased
pursuant to the portion, if any, of this Warrant not exercised by the Purchaser. The Purchaser shall for all purposes hereof be
deemed to have become the Purchaser of record of such Shares on the date on which the Notice of Exercise and payment of the Purchase
Price in accordance with Section 2(a) hereof were delivered and made, respectively, irrespective of the date of delivery
of such certificate or certificates, except that if the date of such delivery, notice and payment is a date when the stock transfer
books of the Company are closed, such person shall be deemed to have become the holder of record of such Shares at the close of
business on the next succeeding date on which the stock transfer books are open. Shares purchased hereunder shall be transmitted
by the transfer agent to the Purchaser by crediting the account of the Purchaser’s prime broker with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Shares to or resale
of the Shares by the Purchaser or (B) the Shares are eligible for resale by the Purchaser without volume or manner-of-sale limitations
pursuant to Rule 144, and otherwise by physical delivery to the address specified by the Purchaser in the Notice of Exercise by
the date that is three Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise and (B) surrender
of this Warrant (if required).

 

3. Adjustment
of Exercise Price and Number of Shares. 

 

(a) Adjustment
for Reclassification, Consolidation or Merger. If while this Warrant, or any portion hereof, remains outstanding and unexpired
there shall be (i) a reorganization or recapitalization (other than a combination, reclassification, exchange or subdivision of
shares otherwise provided for herein), (ii) a merger or consolidation of the Company with or into another corporation or other
entity in which the Company shall not be the surviving entity, or a reverse merger in which the Company shall be the surviving
entity but the shares of the Company’s capital stock outstanding immediately prior to the merger are converted by virtue
of the merger into other property, whether in the form of securities, cash or otherwise, or (iii) a sale or transfer of the Company’s
properties and assets as, or substantially as, an entirety to any other corporation or other entity in one transaction or a series
of related transactions, then, as a part of such reorganization, recapitalization, merger, consolidation, sale or transfer, unless
otherwise directed by the Purchaser, all necessary or appropriate lawful provisions shall be made so that the Purchaser shall
thereafter be entitled to receive upon exercise of this Warrant during the Warrant Exercise Term and upon payment of the Exercise
Price then in effect, the greatest number of shares of capital stock or other securities or property that a holder of the Shares
deliverable upon exercise of this Warrant would have been entitled to receive in such reorganization, recapitalization, merger,
consolidation, sale or transfer if this Warrant had been exercised immediately prior to such reorganization, recapitalization,
merger, consolidation, sale or transfer, all subject to further adjustment as provided in this Section 3. If the per share
consideration payable to the Purchaser for Shares in connection with any such transaction is in a form other than cash or marketable
securities, then the value of such consideration shall be determined in good faith by the Board. The foregoing provisions of this
paragraph shall similarly apply to successive reorganizations, recapitalizations, mergers, consolidations, sales and transfers
and to the capital stock or securities of any other corporation that are at the time receivable upon the exercise of this Warrant.
In all events, appropriate adjustment shall be made in the application of the provisions of this Warrant with respect to the rights
and interests of the Purchaser after the transaction, to the end that the provisions of this Warrant shall be applicable after
that event, as near as reasonably may be, in relation to any shares or other property deliverable or issuable after such reorganization,
recapitalization, merger, consolidation, sale or transfer upon exercise of this Warrant.

 

    3

    

    

 

(b) Adjustments
for Split, Subdivision or Combination of Shares. If the Company shall at any time subdivide (by any stock split, stock dividend,
recapitalization, reorganization, reclassification or otherwise) the shares of Common Stock subject to acquisition hereunder,
then, after the date of record for effecting such subdivision, the Exercise Price in effect immediately prior to such subdivision
will be proportionately reduced and the number of shares of Common Stock subject to acquisition upon exercise of the Warrant will
be proportionately increased. If the Company at any time combines (by reverse stock split, recapitalization, reorganization, reclassification
or otherwise) the shares of Common Stock subject to acquisition hereunder, then, after the record date for effecting such combination,
the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of shares
of Common Stock subject to acquisition upon exercise of the Warrant will be proportionately decreased.

 

(c) Adjustments
for Dividends in Stock or Other Securities or Property. If while this Warrant, or any portion hereof, remains outstanding
and unexpired, the holders of any class of securities as to which purchase rights under this Warrant exist at the time shall have
received or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive,
without payment therefor, other or additional stock or other securities or property (other than cash) of the Company by way of
dividend, then and in each case, this Warrant shall represent the right to acquire, in addition to the number of shares of such
class of security receivable upon exercise of this Warrant, and without payment of any additional consideration therefor, the
amount of such other or additional stock or other securities or property (other than cash) of the Company that such holder would
be entitled to receive had it been the holder of record of the class of security receivable upon exercise of this Warrant on the
record date fixed for the determination of stockholders eligible to receive such dividend, giving effect to all adjustments called
for by the provisions of this Section 3 that occur from such record date to the date of such exercise.

 

(d) [Reserved.]

 

(e) Notice
of Adjustments. Upon any adjustment of the Exercise Price and any increase or decrease in the number of Shares purchasable
upon the exercise of this Warrant, then, and in each such case, the Company, within 30 days thereafter, shall give written notice
thereof to the Purchaser at the address of such Purchaser as shown on the books of the Company, which notice shall state the Exercise
Price as adjusted and, if applicable, the increased or decreased number of Shares purchasable upon the exercise of this Warrant,
setting forth in reasonable detail the method of calculation of each. The Purchaser and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this Section 3, following any adjustment hereunder,
the number of Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

    4

    

    

 

4. Transfer
of Warrant. 

 

(a) Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and
under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or
current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer,
that the Purchaser or transferee of this Warrant, as the case may be, comply with the transfer restrictions of the Subscription
Agreement.

 

(b) Purchaser
Representation. The Purchaser, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon
any exercise hereof, will acquire the Shares issuable upon such exercise, for its own account and not with a view to or for distributing
or reselling such Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except
pursuant to sales registered or exempted under the Securities Act.

 

5.
 Notices. All
notices, requests, consents and other communications required or permitted under this Warrant shall be in writing and shall be
deemed delivered (i) three business days after being sent by registered or certified mail, return receipt requested, postage prepaid
or (ii) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next business day
delivery or (iii) on the business day of delivery if sent by facsimile or electronic transmission, in each case to the intended
recipient as set forth below:

 

If
to the Company to:

 

NeuroOne
Medical Technologies Corporation

10901
Red Circle Drive, Suite 150

Minnetonka,
MN 54343

Attention:
David A. Rosa

Email:
daver@neurooneinc.com

 

With
a copy (that shall not constitute notice) to:

 

Honigman
Miller Schwartz and Cohn LLP

650
Trade Centre Way Suite 200

Portage,
Michigan 49002

Attention:
Phillip D. Torrence

Facsimile:
(269) 337-7703

Email:
ptorrence@honigman.com

 

If
to the Purchaser at its address as furnished in the Subscription Agreement.

 

Either
party may give any notice, request, consent or other communication under this Warrant using any other means, but no such notice,
request, consent or other communication shall be deemed to have been duly given unless and until it is actually received by the
party for whom it is intended. Either party may change the address to which notices, requests, consents or other communications
hereunder are to be delivered by giving the other party notice in the manner set forth in this Section 5.

 

    5

    

    

 

6. Legends.
The Purchaser acknowledges that each certificate
evidencing the Shares acquired upon the exercise of this Warrant will have restrictions upon resale imposed by state and federal
securities laws. Each such certificate shall be stamped or imprinted with a legend substantially in the following form:

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER
APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION
OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

7. Removal
of Legend. Upon request of a holder of a certificate
with the legends required by Section 6 hereof and subject to Section 3(e) of the Registration Rights Agreement attached
as Annex A to the Subscription Agreement, the Company shall issue to such
holder a new certificate free of any transfer legend, if, with such request, the Company shall have received an opinion of counsel
satisfactory to the Company in form and substance to the effect that any transfer by such holder of the Shares evidenced by such
certificate will not violate the Act or any applicable state securities laws.

 

8. Fractional
Shares. No fractional Shares will be issued
in connection with any exercise hereunder. Instead, the Company shall round the number of Shares to be issued up to the nearest
whole Share. This Warrant may only be exercised for whole shares.

 

9. Rights
of Stockholders. Except as expressly provided
in Section 3(c) hereof, the Purchaser, as such, shall not be entitled to vote or receive dividends or be deemed the holder
of the Shares or any other securities of the Company that may at any time be issuable on the exercise hereof for any purpose,
nor shall anything contained herein be construed to confer upon the Purchaser, as such, any of the rights of a stockholder of
the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof,
or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification
of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or otherwise
until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have been issued, as provided
herein.

 

10. Miscellaneous.

 

(a) All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Subscription Agreement. Wherever possible, each provision of this Warrant shall be interpreted in such
manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid
under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating
the remainder of such provisions or the remaining provisions of this Warrant.

 

    6

    

    

 

(b) The
headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

(c) The
terms of this Warrant shall be binding upon and shall inure to the benefit of any successors or permitted assigns of the Company
and of the Purchaser and of the Shares issued or issuable upon the exercise hereof.

 

(d) This
Warrant and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the
parties with regard to the subject hereof.

 

(e) The
Company shall not, by amendment of the certificate of incorporation or bylaws, or through any other means, directly or indirectly,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant and shall at all times in good faith
assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order
to protect the rights of the Purchaser contained herein against impairment.

 

(f) Upon
receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and,
in the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and
amount to the Company, or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company, at
its expense, will execute and deliver to the Purchaser, in lieu thereof, a new Warrant of like date and tenor.

 

(g) This
Warrant and any provision hereof may be amended, waived or terminated only by the written consent of the Company and holders of
a majority in original aggregate principal amount of the units sold in the Private Placement.

 

signature
page follows

 

    7

    

    

 

In
Witness Whereof, the Company has caused this
Warrant to be signed by its duly authorized officer.

 

	 	NeuroOne
    Medical Technologies Corporation
	 	 	 
	 	By:	 
	 	Name:	David A. Rosa
	 	Title:	Chief Executive Officer

 

Signature
Page to

Common Stock Purchase Warrant

 

    

    

    

 

Exhibit
A

 

NOTICE
OF EXERCISE

 

To:NeuroOne
Medical Technologies Corporation

 

(1)
The undersigned hereby elects to purchase ________ Shares of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if
any, in the form of cash in lawful money of the United States.

 

(2)
Please issue said Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The
Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(3)
The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933,
as amended.

 

[purchaser]

 

Name
of Investing Entity: ______________________________________________________________

Signature
of Authorized Signatory of Investing Entity: ________________________________________

Name
of Authorized Signatory: __________________________________________________________

Title
of Authorized Signatory: ___________________________________________________________

Date:
______________________________________________________________________________

 

    A-1

    

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	
	 	(Please
    Print)
	 	 
	Address:	
	 

         

        Phone
        Number:

         

        Email
        Address:
	(Please
        Print)

         

        ______________________________________

         

        ______________________________________

	Dated:
    _______________ __, ______	 
	Holder’s
    Signature:	 
	Holder’s
    Address:Exhibit 10.1

 

SUBSCRIPTION AGREEMENT

 

NeuroOne Medical Technologies Corporation

10901 Red Circle Drive, Suite 150

Minnetonka, MN 54343

 

Ladies and Gentlemen:

 

1. Subscription.
As of [________], 2018, the undersigned (the “Purchaser”), intending to be legally bound, hereby irrevocably
agrees to purchase from NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”),
the number of Units (the “Units”) set forth on the signature page hereof at a purchase price of $2.50
per Unit. Each Unit consists of (i) one share of common stock, par value $0.001 per share, of the Company (the “Common
Stock”), and (ii) one warrant to purchase one share of Common Stock (the “Warrant Shares”)
at an initial exercise price of $3.00 per share (each a “Warrant” and collectively, the “Warrants”),
which will terminate five years following the First Closing.

 

This subscription is submitted
to the Purchaser in accordance with and subject to the terms and conditions described in this Subscription Agreement and the Confidential
Private Placement Memorandum of the Company, dated December 12, 2018, as amended or supplemented from time to time, including
all attachments, schedules and exhibits thereto (the “Memorandum”), relating to the private placement
offering (the “Offering”) by the Company of up to of 4,000,000 Units ($10,000,000) (the “Maximum
Amount”). The Units are being offered by the Company and Paulson Investment Company, LLC (the “Broker”)
on a “reasonable best efforts” basis. The minimum purchase amount is 10,000 Units ($25,000), although the Company may,
in their discretion, accept subscriptions for a lesser number of Units.

 

The Broker will receive a cash
commission equal to 12% of the gross proceeds from the sale of the Units (the “Commission”). In addition
to the Broker’s Commission, the Company will issue 5-year warrants to the Broker to purchase an amount of Common Stock equal
to 10% of the total amount of shares sold in this Offering at an exercise price of $2.75 per share (the “Broker Warrants”
and, together with the Commission, the “Fee”).

 

The terms of the Offering are
more completely described in the Memorandum and such terms are incorporated by reference herein in their entirety. Capitalized
terms not otherwise defined herein shall have the meanings ascribed to such terms in the Memorandum.

 

2. Payment.
The Purchaser encloses herewith a check payable to, or will immediately make a wire transfer payment to the Company in the full
amount of the purchase price of the Units being subscribed for (the “Subscription Amount”) as set forth
in Section 4(e). Wire transfer instructions are set forth on the instruction page accompanying this Subscription Agreement. Such
funds will be returned promptly, without interest or offset if the Purchaser’s subscription is not accepted by the Company
for any reason or no reason, or the Offering is terminated pursuant to its terms by the Company prior to the applicable closing
of the Offering.

 

3. Deposit
of Funds. The Company shall hold all funds in escrow until such time as it closes on the corresponding subscriptions. If the
Company rejects a subscription, either in whole or in part (which decision is in their sole discretion), the rejected subscription
funds or the rejected portion thereof will be returned promptly to the Purchaser without interest accrued thereon.

 

     

    

    

 

4. Deliveries.
On or prior to the applicable closing, Purchaser shall deliver or cause to be delivered the following:

 

(a) to the Company, this Subscription
Agreement, duly executed by the Purchaser;

 

(b) to the Company, the Subscription
Amount, by wire transfer to the Company’s account, as set forth on Schedule I attached hereto;

 

(c) to the Company, the Registration
Rights Agreement, in the form attached hereto as Annex A, duly executed by such Purchaser; and

 

(d) to the Company, a fully completed
and duly executed Accredited Investor Questionnaire, satisfactory to the Company, in the form attached hereto as Annex B.

 

On or prior to the applicable
closing, the Company shall deliver to the Purchaser fully executed and compiled copies of the Subscription Agreement and Registration
Rights Agreement. The Company shall also deliver the executed Warrant in the form attached hereto as Annex C within ten
(10) trading days of the applicable closing date.

 

5. Acceptance
of Subscription. The Purchaser understands and agrees that the Company, in its sole discretion, reserves the right to accept
or reject this or any other subscription for Units, in whole or in part, and for any reason or no reason, notwithstanding prior
receipt by the Purchaser of notice of acceptance of this subscription. The Company shall have no obligation hereunder until the
Subscription Amount is received by the Company and the Company has executed and delivered to the Purchaser a fully executed and
compiled copy of this Subscription Agreement. If this subscription is rejected in whole or the Offering is terminated within the
Offering Period, all funds received from the Purchaser will be returned without interest or offset, and this Subscription Agreement
shall thereafter be of no further force or effect. If this subscription is rejected in part, the funds for the rejected portion
of this subscription will be returned without interest or offset, and this Subscription Agreement will continue in full force and
effect to the extent this subscription was accepted.

 

6. Representations
and Warranties of the Purchaser. The Purchaser hereby acknowledges, represents, warrants and agrees to and with the Company
as follows (it being specifically acknowledged and agreed that the Broker shall be a third party beneficiary of the following):

 

(a) The
Purchaser is aware that an investment in the Units involves a significant degree of risk and has carefully read and considered
the matters set forth in the Memorandum, including but not limited to the section entitled “Risk Factors” in the Memorandum,
and the Company’s filings with the Securities and Exchange Commission (the “SEC”).

 

(b) None
of the securities comprising the Units, including the Common Stock and the Warrants offered pursuant to the Memorandum, or the
Warrant Shares issuable upon conversion of the Warrants, are registered under the Securities Act of 1933, as amended (the “Securities
Act”), or any state securities laws. The Purchaser understands that the offering and sale of the Units (including
the Common Stock and the Warrants) and the Warrant Shares issuable upon conversion of the Warrants are intended to be exempt from
registration under the Securities Act, by virtue of Section 4(a)(2) thereof and the provisions of Regulation D promulgated thereunder
(“Regulation D”), based, in part, upon the representations, warranties and agreements of the Purchaser
contained in this Subscription Agreement.

 

    2

    

    

 

(c) At
the time the Purchaser was offered the Units, it was, at the date hereof it is, an “accredited investor” as defined
in Rule 501(a) under the Securities Act and the Accredited Investor Certification attached hereto as Annex B. The Accredited
Investor Certificate is complete and accurate in all respects as of the date of this agreement, and will continue to be complete
and accurate as of the effectiveness date of the Resale Registration Statement; provided, that the Purchaser shall be entitled
to update such information by providing written notice thereof to the Company.

 

(d) Prior
to the execution of this Subscription Agreement, the Purchaser and the Purchaser’s attorney, accountant, purchaser representative
and/or tax adviser, if any (collectively, the “Advisers”), have received the Memorandum and all other
documents requested by the Purchaser, have carefully reviewed them and the documents filed by the Company with the SEC, and understand
the information contained therein.

 

(e) Neither
the SEC nor any state securities commission or other regulatory authority has approved the Units, the Common Stock, the Warrants,
or the Warrant Shares, or passed upon or endorsed the merits of the offering of Units, or confirmed the accuracy or determined
the adequacy of the Memorandum. The Memorandum has not been reviewed by any federal, state or other regulatory authority.

 

(f) All
documents, records, and books pertaining to the investment in the Units (including, without limitation, the Memorandum) have been
made available for inspection by such Purchaser and its Advisers, if any.

 

(g) The
Purchaser and its Advisers, if any, have had a reasonable opportunity to ask questions of and receive answers from a person or
persons acting on behalf of the Company concerning the Offering, the business and financial condition of the Company, and all such
questions have been answered to the full satisfaction of the Purchaser and its Advisers, if any.

 

(h) In
evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representation or information
(oral or written) other than as stated in or incorporated by reference into the Memorandum or any documents filed by the Company
with the SEC.

 

(i) The
Purchaser is unaware of, is in no way relying on, and did not become aware of the Offering through or as a result of, any form
of general solicitation or general advertising including, without limitation, any article, notice, advertisement or other communication
published in any newspaper, magazine or similar media or broadcast over television, radio or the Internet (including, without limitation,
the Company’s or SEC’s website, internet “blogs,” bulletin boards, discussion groups and social networking
sites) in connection with the Offering and is not subscribing for the Units and did not become aware of the Offering through or
as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by, a person
not previously known to the Purchaser in connection with investments in securities generally.

 

(j) The
Purchaser has taken no action that would give rise to any claim by any person for brokerage commissions, finders’ fees or
the like relating to this Subscription Agreement or the transactions contemplated hereby (other than commissions to be paid by
the Company to the Broker or as otherwise described in the Memorandum) and, in turn, to be paid to its selected dealers.

 

(k) The
Purchaser, together with its Advisers, if any, has such knowledge and experience in financial, tax, and business matters, and,
in particular, investments in securities, so as to enable it to utilize the information made available to it in connection with
the Offering to evaluate the merits and risks of an investment in the Units and the Company and to make an informed investment
decision with respect thereto.

 

    3

    

    

 

(l) The
Purchaser is not relying on the Company, the Broker, or any of their respective employees or agents with respect to the legal,
tax, economic and related considerations of an investment in the Units, and the Purchaser has relied on the advice of, or has consulted
with, only its own Advisers.

 

(m) The
Purchaser is acquiring the Shares and the Warrants and, upon exercise of the Warrants, will acquire the Warrant Shares, as principal
for its own account and not with a view to, or for distributing or reselling such securities or any part thereof in violation of
the Securities Act or any applicable state securities laws, provided, however, that by making the representations herein, the Purchaser
reserves the right, subject to the provisions of this Agreement and the Registration Rights Agreement, at all times to sell or
otherwise dispose of all or any part of such securities pursuant to the Resale Registration Statement under the Securities Act
or under an exemption from such registration and in compliance with applicable federal and state securities laws. The Purchaser
is acquiring the Units hereunder in the ordinary course of its business. The Purchaser does not presently have any agreement, plan
or understanding, directly or indirectly, with any person to distribute or effect any distribution of any of the Units, Common
Stock, Warrants or Warrant Shares issuable upon exercise of the Warrants (or any securities which are derivatives thereof) to or
through any person or entity; the Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity
engaged in a business that would require it to be so registered as a broker-dealer.

 

Legends shall be placed on the
securities included in the Units to the effect that they have not been registered under the Securities Act or applicable state
securities laws. Appropriate notations will be made in the Company’s stock books to the effect that the securities included
in the Units have not been registered under the Securities Act or applicable state securities laws. Stop transfer instructions
will be placed with the transfer agent, if any, on the securities. There can be no assurance that there will be any market for
resale of the Units, the Common Stock, the Warrants, or the Warrant Shares nor can there be any assurance that such securities
will be freely transferable at any time in the foreseeable future.

 

(n) The
Purchaser has adequate means of providing for such Purchaser’s current financial needs and foreseeable contingencies and
has no need for liquidity of its investment in the Units for an indefinite period of time.

 

(o) The
Purchaser (i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority to
execute and deliver this Subscription Agreement and any other agreements, documents or instruments delivered or required to be
delivered together with or pursuant to this Agreement or in connection herewith (the “Transaction Documents”)
and to carry out the provisions hereof and thereof; (ii) if a corporation, partnership, or limited liability company or partnership,
or association, joint stock company, trust, unincorporated organization or other entity, represents that such entity was not formed
for the specific purpose of acquiring the Units, such entity is duly organized, validly existing and in good standing under the
laws of the state of its organization, the consummation of the transactions contemplated hereby is authorized by, and will not
result in a violation of state law or our charter or other organizational documents, such entity has full power and authority to
execute and deliver the Transaction Documents and to carry out the provisions hereof and thereof and to purchase and hold the securities
constituting the Units, the execution and delivery of the Transaction Documents have been duly authorized by all necessary action,
the Transaction Documents to which it is a party have been duly executed and when delivered on behalf of such entity in accordance
with the terms hereof, will constitute a legal, valid and binding obligation of such entity, enforceable against it in accordance
with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by
other equitable principles of general application; or (iii) if executing the Transaction Documents in a representative or fiduciary
capacity, represents that it has full power and authority to execute and deliver the Transaction Documents in such capacity and
on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or limited liability company or partnership,
or other entity for whom the Purchaser is executing the Transaction Documents, and such individual, partnership, ward, trust, estate,
corporation, or limited liability company or partnership, or other entity has full right and power to execute and deliver the Transaction
Documents and all other related agreements or certificates and to carry out the provisions hereof and thereof and to purchase and
hold the securities constituting the Units, and represents that the Transaction Documents constitute a legal, valid and binding
obligation of such entity. The execution, delivery and performance of this Subscription Agreement, including the Registration Rights
Agreement, and the consummation by Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation
of the organizational documents of the Purchaser (except as to any Purchaser who is a natural person), (ii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Purchaser is a party,
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities
laws) applicable to the Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or
violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability
of the Purchaser to perform its obligations hereunder.

 

    4

    

    

 

(p) The
Purchaser and its Advisers, if any, have had the opportunity to obtain any additional information, to the extent the Company had
such information in its possession or could acquire it without unreasonable effort or expense, necessary to verify the accuracy
of the information contained in the Memorandum and all documents received or reviewed in connection with the purchase of the Units
and have had the opportunity to have representatives of the Company provide them with such additional information regarding the
terms and conditions of this particular investment and the financial condition, results of operations, business of the Company
deemed relevant by the Purchaser or the Advisers, if any, and all such requested information, to the extent the Company had such
information in its possession or could acquire it without unreasonable effort or expense, has been provided to the full satisfaction
of the Purchaser and the Advisers, if any.

 

(q) Any
information which the Purchaser has heretofore furnished or is furnishing herewith to the Company or the Broker is complete and
accurate and may be relied upon by the Company and such broker in determining the availability of an exemption from registration
under federal and state securities laws in connection with the offering of securities as described in the Memorandum. The Purchaser
further represents and warrants that it will notify and supply corrective information to the Company and such broker immediately
upon the occurrence of any change therein occurring prior to the Company’s issuance of the securities contained in the Units.

 

(r) The
Purchaser has significant prior investment experience, including investment in non-registered, high risk securities. The Purchaser
is knowledgeable about investment considerations in development-stage companies. The Purchaser has a sufficient net worth to sustain
a loss of its entire investment in the Company in the event such a loss should occur. The Purchaser’s overall commitment
to investments which are not readily marketable is not excessive in view of the Purchaser’s net worth and financial circumstances
and the purchase of the Units will not cause such commitment to become excessive. The investment is a suitable one for the Purchaser.

 

(s) The
Purchaser is satisfied that the Purchaser has received adequate information with respect to all matters which it or its Advisers,
if any, consider material to the Purchaser’s decision to make this investment.

 

    5

    

    

 

(t) The
Purchaser acknowledges that any estimates or forward-looking statements or projections included in the Memorandum were prepared
by the Company in good faith but that the attainment of any such projections, estimates or forward-looking statements cannot be
guaranteed by the Company and should not be relied upon.

 

(u) No
oral or written representations have been made, or oral or written information furnished, to the Purchaser or the Advisers, if
any, in connection with the Offering which are in any way inconsistent with the information contained in the Memorandum or incorporated
by reference in the Memorandum.

 

(v) Within
five (5) days after receipt of a request from the Company, the Purchaser will provide such information and deliver such documents
as may reasonably be necessary to comply with any and all laws and ordinances to which the Company is subject.

 

(w) NEITHER
THE SECURITIES OFFERED HEREBY NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES
AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OR PURUSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE
TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

(x) The
Purchaser acknowledges that none of the Units, the Common Stock, the Warrants, or the Warrant Shares issuable upon exercise of
the Warrants have been recommended by any federal or state securities commission or regulatory authority. In making an investment
decision investors must rely on their own examination of the Company and the terms of the Offering, including the merits and risks
involved. Furthermore, the foregoing authorities have not confirmed the accuracy or determined the adequacy of this Subscription
Agreement or the Memorandum. Any representation to the contrary is a criminal offense. The Units, the Common Stock, the Warrants,
and the Warrant Shares issuable upon exercise of the Warrants are subject to restrictions on transferability and resale and may
not be transferred or resold except as permitted under the Securities Act, and the applicable state securities laws, pursuant to
registration or exemption therefrom. The Purchaser should be aware that it will be required to bear the financial risks of this
investment for an indefinite period of time.

 

(y) (For
ERISA plans only) The fiduciary of the ERISA plan (the “Plan”) represents that such fiduciary has
been informed of and understands the Company’s investment objectives, policies and strategies, and that the decision to invest
“plan assets” (as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA that require
diversification of plan assets and impose other fiduciary responsibilities. The Purchaser fiduciary or Plan (a) is responsible
for the decision to invest in the Company; (b) is independent of the Company or any of its affiliates; (c) is qualified to make
such investment decision; and (d) in making such decision, the Purchaser fiduciary or Plan has not relied primarily on any advice
or recommendation of the Company or any of its affiliates.

 

    6

    

    

 

(z) The
Purchaser should check the Office of Foreign Assets Control (“OFAC”) website at <http://www.treas.gov/ofac>
before making the following representations. The Purchaser represents that the amounts invested by it in the Offering were
not and are not directly or indirectly derived from activities that contravene federal, state or international laws and regulations,
including anti-money laundering laws and regulations. Federal regulations and Executive Orders administered by OFAC prohibit, among
other things, the engagement in transactions with, and the provision of services to, certain foreign countries, territories, entities
and individuals. The lists of OFAC prohibited countries, territories, persons and entities can be found on the OFAC website at
<http://www.treas.gov/ofac>. In addition, the programs administered by OFAC (the “OFAC Programs”)
prohibit dealing with individuals1 or entities in certain countries regardless of whether such individuals or entities
appear on the OFAC lists.

 

(aa)To the best of the Purchaser’s
knowledge, none of: (1) the Purchaser; (2) any person controlling or controlled by the Purchaser; (3) if the Purchaser is a privately-held
entity, any person having a beneficial interest in the Purchaser; or (4) any person for whom the Purchaser is acting as agent or
nominee in connection with this investment is a country, territory, individual or entity named on an OFAC list, or a person or
entity prohibited under the OFAC Programs. Please be advised that the Company may not accept any amounts from a prospective investor
if such prospective investor cannot make the representation set forth in the preceding paragraph. The Purchaser agrees to promptly
notify the Company and the Broker should the Purchaser become aware of any change in the information set forth in these representations.
The Purchaser understands and acknowledges that, by law, the Company may be obligated to “freeze the account” of the
Purchaser, either by prohibiting additional subscriptions from the Purchaser, declining any redemption requests and/or segregating
the assets in the account in compliance with governmental regulations, and the Broker may also be required to report such action
and to disclose the Purchaser’s identity to OFAC. The Purchaser further acknowledges that the Company may, by written notice
to the Purchaser, suspend the redemption rights, if any, of the Purchaser if the Company reasonably deems it necessary to do so
to comply with anti-money laundering regulations applicable to the Company and the Broker or any of the Company’s other service
providers. These individuals include specially designated nationals, specially designated narcotics traffickers and other parties
subject to OFAC sanctions and embargo programs.

 

(bb)To the best of the Purchaser’s
knowledge, none of: (1) the Purchaser; (2) any person controlling or controlled by the Purchaser; (3) if the Purchaser is a privately-held
entity, any person having a beneficial interest in the Purchaser; or (4) any person for whom the Purchaser is acting as agent or
nominee in connection with this investment is a senior foreign political figure,2 or any immediate family3
member or close associate4 of a senior foreign political figure, as such terms are defined in the footnotes below.

 

 

 

1
       These individuals include specially designated nationals, specially designated narcotics
traffickers and other parties subject to OFAC sanctions and embargo programs.

 

2
       A “senior foreign political figure” is defined as a senior official in the
executive, legislative, administrative, military or judicial branches of a foreign government (whether elected or not), a senior
official of a major foreign political party, or a senior executive of a foreign government-owned corporation. In addition, a “senior
foreign political figure” includes any corporation, business or other entity that has been formed by, or for the benefit
of, a senior foreign political figure.

 

3
       “Immediate family” of a senior foreign political figure typically includes
the figure’s parents, siblings, spouse, children and in-laws.

 

4
        A “close associate” of a senior foreign political figure is
a person who is widely and publicly known to maintain an unusually close relationship with the senior foreign political figure,
and includes a person who is in a position to conduct substantial domestic and international financial transactions on behalf
of the senior foreign political figure.

 

    7

    

    

 

(cc)If the Purchaser is affiliated
with a non-U.S. banking institution (a “Foreign Bank”), or if the Purchaser receives deposits from, makes
payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Purchaser represents and warrants
to the Company that: (1) the Foreign Bank has a fixed address, other than solely an electronic address, in a country in which the
Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank maintains operating records related to its banking
activities; (3) the Foreign Bank is subject to inspection by the banking authority that licensed the Foreign Bank to conduct banking
activities; and (4) the Foreign Bank does not provide banking services to any other Foreign Bank that does not have a physical
presence in any country and that is not a regulated affiliate.

 

(dd) Other than with respect
to the transactions contemplated herein, since the time that such Purchaser was first contacted by the Company, a broker or any
other person regarding the transactions contemplated hereby, (i) neither the Purchaser (ii) nor any affiliate of such Purchaser
that (x) had knowledge of the transactions contemplated hereby, (y) has or shares discretion relating to such Purchaser’s
investments or trading or information concerning such Purchaser’s investments, including in respect of the Units, and (z)
is subject to such Purchaser’s review or input concerning such Affiliate’s investments or trading (collectively, “Trading
Affiliates”) has directly or indirectly, nor has any person acting on behalf of or pursuant to any understanding
with such Purchaser or Trading Affiliate, effected or agreed to effect any purchases or sales of the securities of the Company
(including, without limitation, any short sales involving the Company’s securities). Notwithstanding the foregoing, in the
case of a Purchaser and/or Trading Affiliate that is, individually or collectively, a multi-managed investment bank or vehicle
whereby separate portfolio managers manage separate portions of such Purchaser’s or Trading Affiliate’s assets and
the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser’s or Trading Affiliate’s assets, the representation set forth above shall apply only with respect
to the portion of assets managed by the portfolio manager that have knowledge about the financing transaction contemplated by this
Subscription Agreement. Other than to other persons party to this Subscription Agreement, such Purchaser has maintained the confidentiality
of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).

 

(ee) The Purchaser is aware that
the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Common Stock and other activities with
respect to the Common Stock by the Purchaser.

 

(ff) The purchase by the Purchaser
of the Common Stock and Warrants issuable to it at closing will not result in the Purchaser (individually or together with any
other person with whom such Purchaser has identified, or will have identified, itself as part of a “group” in a public
filing made with the SEC involving the Company’s securities) acquiring, or obtaining the right to acquire, in excess of 19.999%
of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction basis that assumes that such
closing shall have occurred. The Purchaser does not presently intend to, alone or together with others, make a public filing with
the SEC to disclose that it has (or that it together with such other persons have) acquired, or obtained the right to acquire,
as a result of such closing (when added to any other securities of the Company that it or they then own or have the right to acquire),
in excess of 19.999% of the outstanding shares of Common Stock or the voting power of the Company on a post transaction basis that
assumes that each closing shall have occurred.

 

(gg) If the Purchaser is an officer
of the Company or beneficial owner of 20% or more of the Company’s outstanding voting equity securities, such Purchaser does
not qualify as a “bad actor” within the meaning of Rule 506(d) under the Securities Act.

 

    8

    

    

 

(hh) The Purchaser acknowledges
that it has received notice that a Member of the Board of Managers, and principal of the Broker, Robert J. Setteducati, entered
into a final settlement with the Massachusetts Securities Division in 2001 pursuant to which he agreed, among other things, never
to seek to register with the Massachusetts Securities Division in any capacity. The settlement resolved allegations that Mr. Setteducati
failed to adequately supervise employees at a prior broker-dealer.

 

7. Company
Representations and Warranties. The Company represents and warrants to the Purchaser, except as and to the extent set forth
in the publicly available reports, schedules, forms, statements and other documents filed by the Company with, or furnished by
the Company to, the SEC as of the date hereof and as of each closing:

 

(a) The
Company is a corporation duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation
and has the requisite corporate power and authority to own its properties and to carry on its business as presently conducted.
The Company is (or will be) duly qualified as a foreign corporation to do business and is (or will be) in good standing in each
jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary.

 

(b) The
Company has all corporate right, power and authority to enter into the Transaction Documents and to consummate the transactions
contemplated hereby. All corporate action on the part of the Company, its directors and stockholders necessary for the: (i) authorization,
execution, delivery and performance of the Transaction Documents by the Company; (ii) authorization, sale, issuance and delivery
of the Shares and Warrants contemplated hereby and the performance of the Company’s obligations hereunder; and (iii) authorization
and reservation for issuance of the Warrant Shares issuable upon exercise of the Warrants, has been taken. The Warrant Shares will
be validly issued, fully paid and nonassessable. The issuance and sale of the securities contemplated hereby will not give rise
to any preemptive rights or rights of first refusal on behalf of any person which have not been waived in connection with this
Offering. The Company is not in default of any other obligations.

 

(c) Assuming
this Subscription Agreement has been duly and validly authorized, executed and delivered by the parties hereto and thereto other
than the Company, this Subscription Agreement is duly authorized, executed and delivered by the Company and constitutes the legal,
valid and binding obligations of the Company enforceable against the Company in accordance with its terms, except as such enforcement
is limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors
rights generally.

 

(d) The
execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated
hereby and thereby (including, without limitation, the issuance of the Shares, the Warrants and the Warrant Shares issuable upon
exercise of the Warrants) will not (i) result in a violation of the Certificate of Incorporation of the Company or other organizational
documents of the Company, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would
become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement,
indenture or instrument to which the Company is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment
or decree applicable to the Company by which any property or asset of the Company is bound or affected.

 

(e) The
Company owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets,
licenses, information and other proprietary rights and processes necessary for its business as now conducted without any known
infringement of the rights of others. The Company has not received any written communications alleging that the Company has violated
or, by conducting its business as presently proposed to be conducted, would violate any of the patents, trademarks, service marks,
trade names, copyrights or trade secrets or other proprietary rights of any other person or entity.

 

    9

    

    

 

(f) The
Company has good and marketable title to its properties and assets, and good title to its leasehold estates, in each case subject
to no mortgage, pledge, lien, lease, encumbrance or charge, other than (i) those resulting from taxes which have not yet become
delinquent; (ii) liens and encumbrances which do not materially detract from the value of the property subject thereto or materially
impair the operations of the Company; and (iii) those that have otherwise arisen in the ordinary course of business. The Company
is in compliance with all material terms of each lease to which it is a party or is otherwise bound.

 

(g) The
Company is not an “investment company” within the meaning of such term under the Investment Company Act of 1940, as
amended, and the rules and regulations of the SEC thereunder.

 

(h) Neither
the Company nor any person participating on the Company’s behalf in the transactions contemplated hereby has conducted any
“general solicitation,” as such term is defined in Regulation D promulgated under the Securities Act, with respect
to any of the securities being offered hereby.

 

(i) The
Company agrees to file a Form D with respect to the sale of the securities offered hereby under Regulation D of the rules and regulations
promulgated under the Securities Act. The Company shall take such action as the Company shall reasonably determine is necessary
to qualify the such securities for sale to the Purchaser pursuant to this Subscription Agreement under applicable securities or
“blue sky” laws of the states of the United States (or to obtain an exemption from such qualification).

 

Neither the Company, nor any
of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales in any security
or solicited any offers to buy any security under circumstances that would require registration under the Securities Act of the
issuance of the Units, the Common Stock, the Warrants or Warrant Shares. The issuance of the Units, the Common Stock, the Warrants
and Warrant Shares will not be integrated with any other issuance of the Company’s securities (past, current or future) such
that the offering of the Units, the Common Stock, the Warrants or Warrant Shares would require registration under the Securities
Act or would require stockholder approval.

 

(j) The
execution, delivery and performance of this Subscription Agreement by the Company will not (i) violate any law, treaty, rule or
regulation applicable to or binding upon the Company or any of its properties or assets, or (ii) result in a breach of any contractual
obligation to which the Company is a party or by which it or any of its properties or assets is bound that would reasonably be
expected to have a material adverse effect on the ability of the Company to perform its obligations under this Subscription Agreement.

 

8. Registration
Rights. Contemporaneously with the execution and delivery of this Agreement, the parties hereto are executing and delivering
a Registration Rights Agreement pursuant to which, among other things, the Company will agree to provide certain registration rights
with respect to the Shares and the Warrant Shares under the Securities Act and the rules and regulations promulgated thereunder
and applicable state securities laws.

 

9. Indemnification.
The Purchaser agrees to indemnify and hold harmless the Company, the Broker, and their respective officers, directors, members,
shareholders, partners, representatives, employees, agents, control persons and affiliates from and against all losses, obligations,
liabilities, claims, damages, contingencies, judgments, fines, penalties, charges, costs, fees and expenses whatsoever (including,
but not limited to, any and all expenses incurred in investigating, preparing or defending against any action, claim, suit, inquiry,
proceeding, investigation, appeal or litigation commenced or threatened by or before any court or governmental, administrative,
or other regulatory agency, body or the SEC) (i) arising out of or based upon any untrue statement or untrue statement of a material
fact made by Purchaser and contained in this Subscription Agreement; or (ii) arise out of or are based upon any breach by Purchaser
of any representation, warranty, or agreement made by Purchaser contained herein.

 

    10

    

    

 

10. Irrevocability;
Binding Effect. The Purchaser hereby acknowledges and agrees that the subscription hereunder is irrevocable by the Purchaser,
except as required by applicable law, and that this Subscription Agreement shall survive the death or disability of the Purchaser
and shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal
representatives, and permitted assigns. If the Purchaser is more than one person, the obligations of the Purchaser hereunder shall
be joint and several and the agreements, representations, warranties, and acknowledgments herein shall be deemed to be made by
and be binding upon each such person and such person’s heirs, executors, administrators, successors, legal representatives,
and permitted assigns.

 

11. Immaterial
Modifications to the Transaction Documents. The Company may, at any time prior to the applicable closing, modify the Warrant
and any other Transaction Document without first providing notice or obtaining prior consent of the Purchaser, if, and only if,
such modification does not materially adversely affect a purchaser’s rights.

 

12. Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via e-mail transmission or facsimile (provided the sender receives a machine-generated confirmation of successful transmission)
at the facsimile number specified in this Section 12 prior to 5:00 P.M., New York City time, on a trading day, (b) the next trading
day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified
in this Section 12 on a day that is not a trading day or later than 5:00 P.M., New York City time, on any trading day, (c) the
trading day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery
specified, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and
communications shall be as follows:

 

	 	If to the Company to:	 	
        NeuroOne Medical Technologies Corporation

        10901 Red Circle Drive, Suite 150

        Minnetonka, MN 54343

        Telephone: (952) 237-7412

        Attention: David A. Rosa

        Email: daver@neurooneinc.com

	 	 	 	 
	 	With copies to:	 	
        Honigman Miller Schwartz and Cohn LLP

        650 Trade Centre Way, Suite 200

        Kalamazoo, MI 49002

        Telephone No.: (269) 337-7702

        Facsimile No.: (269) 337-7703

        Attention: Phillip D. Torrence

        E-mail: PTorrence@honigman.com

	 	 	 	 
	 	If to the Purchaser to:	 	The address set forth on the signature page hereto

 

    11

    

    

 

13. Assignability.
The provisions of this Subscription Agreement shall inure to the benefit of and be binding upon the parties and their successors
and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without the prior
written consent of the Purchaser holding or having rights to acquire the Units, Common Stock, Warrants or Warrant Shares issuable
upon exercise of the Warrants at the time of such consent. The Purchaser may assign its rights hereunder in whole or in part to
any person to whom the Purchaser assigns or transfers any Units, Common Stock, Warrants or Warrant Shares issuable upon exercise
of the Warrants in compliance with the Transaction Documents and applicable law, provided such transferee shall agree in writing
to be bound, with respect to the transferred Units, Common Stock, Warrants or Warrant Shares issuable upon exercise of the Warrants,
by the terms and conditions of this Agreement that apply to the Purchaser.

 

14. Applicable
Law. All questions concerning the construction, validity, enforcement and interpretation of this Subscription Agreement shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof (except Sections 5-1401 and 5-1402 of the General Obligations Law).

 

15. Arbitration.
The parties agree to submit all controversies to arbitration in accordance with the provisions set forth below and understand that:
(a) arbitration is final and binding on the parties; (b) the parties are waiving their right to seek remedies in court, including
the right to a jury trial; (c) pre-arbitration discovery is generally more limited and different from court proceedings; (d) the
arbitrator’s award is not required to include factual findings or legal reasoning and any party’s right to appeal or
to seek modification of rulings by arbitrators is strictly limited; and (e) the panel of arbitrators will typically include a minority
of arbitrators who were or are affiliated with the securities industry.

 

      All controversies which may arise
between the parties concerning this Subscription Agreement shall be determined by arbitration pursuant to the rules then pertaining
to the American Arbitration Association in Minneapolis, Minnesota. The arbitration shall be governed by the Federal Arbitration
Act, 9 U.S.C. Sec. 1-16, and the judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction
thereof. Any notice of such arbitration or for the confirmation of any award in any arbitration shall be sufficient if given in
accordance with the provisions of this Agreement. The parties agree that the determination of the arbitrators shall be binding
and conclusive upon them.

 

16. Blue
Sky Qualification. The purchase of Units under this Subscription Agreement is expressly conditioned upon the exemption from
qualification of the offer and sale of the Units from applicable federal and state securities laws. The Company shall not be required
to qualify this transaction under the securities laws of any jurisdiction, but to the extent we proceed with the Offering and effect
one or more closings, the Company shall take such action as the Company shall reasonably determine is necessary to qualify the
securities for sale to the Purchaser pursuant to this Subscription Agreement under applicable securities or “blue sky”
laws of the states of the United States (or to obtain an exemption from such qualification).

 

17. Use
of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, neuter,
singular or plural as the identity of the person or persons referred to may require.

 

18. Confidentiality.
The Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or about the Company, not otherwise
properly in the public domain, was received in confidence. The Purchaser agrees not to divulge, communicate or disclose, except
as may be required by law or for the performance of this Subscription Agreement, or use to the detriment of the Company or for
the benefit of any other person or persons, or misuse in any way, any confidential information of the Company, including any scientific,
technical, trade or business secrets of the Company and any scientific, technical, trade or business materials that are treated
by the Company as confidential or proprietary, including, but not limited to, ideas, discoveries, inventions, developments and
improvements belonging to the Company and confidential information obtained by or given to the Company about or belonging to third
parties.

 

    12

    

    

 

19. Miscellaneous.

 

(a) This
Subscription Agreement (including the annexes hereto), together with the Transaction Documents (which are to be issued or executed
at closing), constitute the entire agreement between the Purchaser and the Company with respect to the subject matter hereof and
supersede all prior oral or written agreements and understandings, if any, relating to the subject matter hereof.

 

(b) The
representations and warranties and covenants of the Company and the Purchaser made in this Subscription Agreement (including the
annexes hereto) shall survive the execution and delivery hereof and delivery of the Units, Common Stock, Warrants and Warrant Shares
issuable upon exercise of the Warrants.

 

(c) Each
of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others
engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the
transactions contemplated hereby are consummated.

 

(d) This
Subscription Agreement may be executed in one or more counterparts each of which shall be deemed an original (including signatures
sent by facsimile transmission or by email transmission of a PDF scanned document), but all of which shall together constitute
one and the same instrument.

 

(e) Each
provision of this Subscription Agreement shall be considered separable and, if for any reason any provision or provisions hereof
are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair the operation of or
affect the remaining portions of this Subscription Agreement.

 

(f) Paragraph
titles are for descriptive purposes only and shall not control or alter the meaning of this Subscription Agreement as set forth
in the text.

 

(g) The
Purchaser understands and acknowledges that there may be multiple closings for this Offering.

 

(i) In
addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Purchaser
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages
may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence
and hereby agree to waive in any action for specific performance of any such obligation (other than in connection with any action
for a temporary restraining order) the defense that a remedy at law would be adequate.

 

 

	[The below is intended to be blank]

 

    13

    

    

 

SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT

 

As of the date first written above, Purchaser
hereby elects to subscribe under the Subscription Agreement for a total of __________ Units at a price of $2.50 per Unit (NOTE:
to be completed by Purchaser) and executes the Subscription Agreement.

 

If the Purchaser is an INDIVIDUAL, and if purchased
as JOINT TENANTS, as TENANTS IN COMMON, as COMMUNITY PROPERTY, or as an INDIVIDUAL RETIREMENT ACCOUNT:

 

	 	 	 	 	 
	 	Print
    Name(s)	 	Social
    Security Number(s)	 
	 	 	 	 	 
	 	 	 	 	 
	 	Signature(s)
    of Subscriber(s)	 	Signature	 
	 	 	 	 	 
	 	 	 	 	 
	 	Date	 	Address	 
	 	 	 	 	 
	 	 	 	 	 
	 	Email
    Address	 	 	 

 

If
the Purchaser is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY or TRUST:

 

	 	 	 	 	 
	 	Name
    of Partnership, 

    Corporation, Limited

    Liability Company or Trust	 	Federal
    Taxpayer

    Identification Number	 

 

	 	By:	 	 	 	 
	 		Name:	 	State
    of Organization	 
	 		Title:	 	 	 

 

	 	 	 	 	 
	 	Date	 	Address	 
	 	 	 	 	 
	 		 	 	 
	 	Email
    Address	 	 	 

  

NEUROONE
MEDICAL TECHNOLOGIES

CORPORATION

 

	By:	 	 
	Name:	 	 
	Title:	 	 

 

    14

    

    

 

Schedule 1

 

To subscribe for Units in the private offering of NeuroOne Medical
Technologies Corporation:

 

	1.	Fill in the number of Units being purchased and Complete and Sign the Signature Page of the Subscription Agreement.

 

	2.	Initial and Complete the Accredited Investor Certification page attached to this letter.

 

	3.	Send all executed documents and payment to:

 

	 	o	Account Name: NeuroOne Medical Technologies Corporation 

 

	 	o	Company Address: 10901 Red Circle Drive, Suite 150, Minnetonka, MN 54343

 

	 	o	Account Number: 7078027

 

	 	o	Bank: Square 1 Bank, 111 S Corcoran St, Durham, NC 27701

 

	 	o	Routing Number: 053112615

 

	 	o	SWIFT Code: SQARUS33

  

		FBO:	Investor Name
	 	 	Social Security Number

Address

 

     

    

    

 

Annex A

Form of Registration Rights Agreement

 

     

    

    

 

Annex B

NEUROONE MEDICAL TECHNOLOGIES CORPORATION

ACCREDITED INVESTOR CERTIFICATION

 

For Individual Investors Only

(all Individual Investors must INITIAL
where appropriate):

 

	Initial	 	 	I
    have a net worth in excess of $1 million, either individually or through aggregating my individual holdings and those in which
    I have a joint, community property or other similar shared ownership interest with my spouse. For purposes of the foregoing
    net worth calculation, I have excluded the value of my/our primary residence, after deducting any mortgage securing such primary
    residence. 
	Initial	 	 	I
    have had an annual gross income for the past two years of at least $200,000 (or $300,000 jointly with my spouse) and expect
    my income (or joint income, as appropriate) to reach the same level in the current year.
	Initial	 	 	I
    am a director or executive officer of NeuroOne Medical Technologies Corporation.
	 	 	 	 

 

For Non-Individual Investors

(all Non-Individual Investors must INITIAL
where appropriate):

 

	Initial	 	 	The investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons who meet at least one of the criteria for Individual Investors set forth above.
	 	 	 
	Initial	 	 	The investor certifies that it is a partnership, corporation, limited liability company or business trust that has total assets of at least $5 million and was not formed for the purpose of investing in the Company.
	 	 	 
	Initial	 	 	The investor certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a bank, savings and loan association, insurance company or registered investment adviser.
	 	 	 
	Initial	 	 	The investor certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the date of this Agreement.
	 	 	 
	Initial	 	 	The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who meet either of the criteria for Individual Investors.
	 	 	 
	Initial	 	 	The investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual or fiduciary capacity.
	 	 	 
	Initial	 	 	The undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
	 	 	 
	Initial	 	 	The investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding $5,000,000 and not formed for the specific purpose of investing in the Company.
	 	 	 
	Initial	 	 	The investor certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific purpose of investing in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment.
	 	 	 
	Initial	 	 	The investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000.
	 	 	 
	Initial	 	 	The investor certifies that it is an insurance company as defined in §2(a)(13) of the Securities Act, or a registered investment company.
	 	 	 

  

 

	 	 	 
	Investor Signature	 	Date

 

     

    

    

 

Annex C

Form of Warrant

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]